Company Information
Maze Therapeutics was founded on January 2018. The company is based in Redwood City, CA, USA . The number of employees in Maze Therapeutics is less than 50. Maze therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines.Funding & investors
Maze Therapeutics has received 2 rounds of venture funding. The total funding amount is around $191M.- City Hill Ventures (Venture capital)
- ARCH Venture Partners (Venture capital)
- Third Rock Ventures (Venture capital)
- Alexandria Venture Investments (Venture capital)
- Foresite Capital (Private equity firm)
- Contact us if you are interested to see all 8 investors
Similar Companies [beta]
- Coherus biosciences
- Carmot therapeutics
- Scout bio
- Yumanity therapeutics
- Genoox
- Cellics therapeutics
- More...
Venture Categories
Active Venture Investors
- Active Investors in Biotechnology
- Active Investors in Health Care
- Active Investors in Science And Engineering
- Active Investors in Wellness
Venture Competitors
- Best Funded Biotechnology Startups
- Best Funded Health Care Startups
- Best Funded Science And Engineering Startups
- Best Funded Wellness Startups
News
Maze Therapeutics - Blog
- Maze Therapeutics Announces Publication in Nature Describing a Novel Mechanism Linking Well-Established Genetic Drivers of ALS and FTD
- Maze Therapeutics Announces Phase 1 Trial Initiation Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
- Maze Therapeutics Presents New Preclinical Data Supporting Advancement of MZE001 as a Potential Treatment for Pompe Disease
- Maze Therapeutics to Present Preclinical Data Highlighting MZE001 as a Potential Treatment for Pompe Disease at 2022 WORLD Symposium
- Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically Defined Diseases
- Maze Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Maze Therapeutics Announces Publication in Nature Describing a Novel Mechanism Linking Well-Established Genetic Drivers of ALS and FTD Findings Highlight Applicability of Maze’s Compass Platform to Identify and Provide Insight into Disease-Causing Genetic Variants to Treat Patients in Need SOUTH...
Maze Therapeutics Announces Phase 1 Trial Initiation Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease SOUTH SAN FRANCISCO, CA., Feb. 17, 2022 – Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the...
Maze Therapeutics Presents New Preclinical Data Supporting Advancement of MZE001 as a Potential Treatment for Pompe Disease Findings Highlight Potential of Oral Substrate Reduction Therapy to Lower Disease-Causing Glycogen Build-up as a Treatment for Pompe Disease Data Support Advancement...
Maze Therapeutics to Present Preclinical Data Highlighting MZE001 as a Potential Treatment for Pompe Disease at 2022 WORLD Symposium SOUTH SAN FRANCISCO, CA., January 31, 2022 – Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced...
Business Wire Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically Defined Diseases Clinical Trial Initiation of MZE001 for Pompe Disease Expected in First Half of 2022 Andy Tran...
SOUTH SAN FRANCISCO, CA, January 5, 2022 – Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Jason Coloma, Ph.D, president and chief executive officer of Maze, will present a company overview at the 40th...
Share:
